A. Santarosa

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

G. Salles, A. Zelenetz, S. Horwitz, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.

M. Geyer, G. Inghirami, S. Horwitz, 2021, Blood.

Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

A. Zelenetz, S. Horwitz, A. Intlekofer, 2020 .

PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N‐AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA

K. Savage, H. Schoder, A. Dogan, 2023, Hematological Oncology.